Drug Profile
TAC 201
Alternative Names: TAC-201Latest Information Update: 29 Jul 2015
Price :
$50
*
At a glance
- Originator Meiji Dairies Corporation
- Developer Taiho Pharmaceutical
- Class Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Seasonal allergic rhinitis
Most Recent Events
- 31 Mar 2015 Discontinued - Phase-II for Seasonal allergic rhinitis in Japan (SC)